Tiziana Life Sciences PLC Publication of Prospectus (1708J)
December 18 2020 - 6:13AM
UK Regulatory
TIDMTILS
RNS Number : 1708J
Tiziana Life Sciences PLC
18 December 2020
This announcement is an advertisement and not a prospectus.
Neither this announcement nor anything contained herein shall form
the basis of, or be relied upon in connection with, any offer or
commitment whatsoever in any jurisdiction. Investors should not
purchase any transferable securities referred to in this
announcement except on the basis of information contained in the
prospectus (the "Prospectus") in its final form that is published
by Tiziana Life Sciences plc in connection with the admission of
the Company's ordinary shares (the "Ordinary Shares") to listing on
the standard segment of the Official List of the Financial Conduct
Authority (the "FCA") and to trading on the main market for listed
securities (the "Main Market") of London Stock Exchange plc (the
"London Stock Exchange"). This announcement is not an offer to
sell, or a solicitation of an offer to acquire, securities in the
United States, Australia, Canada, Japan or in any other
jurisdiction.
Tiziana Life Sciences PLC
("Tiziana" or "the Company")
Publication of Prospectus
London, New York, 18 December 2020 - Tiziana Life Sciences plc
(Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a
biotechnology company focused on innovative therapeutics for
oncology, inflammation and infectious diseases, today announces,
further to the announcement of 17 December 2020, that the Company
has issued a prospectus in connection with its admission to listing
of its ordinary shares (the "Ordinary Shares") on the standard
listing segment of the Official List of the Financial Conduct
Authority ("FCA") (the "Official List") and admission to trading on
the main market for listed securities (the "Main Market") of London
Stock Exchange plc (the "London Stock Exchange") (together,
"Admission").
Expected timetable
Publication of Prospectus 18 December 2020
Last day of trading of the Shares on AIM 20 January 2021
Expected delisting of the Shares from 7.00 am on 21 January
AIM 2021
Expected admission of the Shares to the 8.00 am on 21 January
Official List 2021
Expected commencement of dealings of the 8.00 am on 21 January
Shares on the Main Market 2021
The times and dates set out in the expected timetable of
principal events above and mentioned in this document, and in any
other document issued in connection with Admission are subject to
change by the Company, in which event details of the new times and
dates will be notified to the FCA, the London Stock Exchange and,
where appropriate, shareholders.
The Prospectus was approved by the FCA on 18 December 2020 and
is available to be viewed on the Company's website at:
www.tizianalifesciences.com . An electronic copy of the Prospectus
will also be submitted to the National Storage Mechanism and will
be available shortly for inspection at:
https://data.fca.org.uk/#/nsm/nationalstoragemechanism .
Tiziana Life Sciences plc is a company incorporated in England
and Wales with company number 03508592. The Ordinary Shares are
registered with ISIN GB00BKWNZY55, SEDOL code BKWNZY5 and TIDM
TILS. It is expected that Admission will become effective and that
dealings will commence at 8.00 am on 21 January 2021. Trading in
the Company's shares on AIM will be cancelled simultaneously with
Admission.
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014. The person who arranged the
release of this information is Keeren Shah, Finance Director of
Tiziana.
About Tiziana Life Sciences
Tiziana Life Sciences plc is a dual listed (NASDAQ: TLSA &
UK AIMS: TILS) biotechnology company that focuses on the discovery
and development of novel molecules to treat human diseases in
oncology, inflammation and infectious diseases. In addition to
milciclib, the Company will be shortly initiating phase 2 studies
with orally administered foralumab for Crohn's Disease and nasally
administered foralumab for progressive multiple sclerosis.
Foralumab is the only fully human anti-CD3 monoclonal antibody
(mAb) in clinical development in the world. This phase II compound
has potential application in a wide range of autoimmune and
inflammatory diseases, such as Crohn's Disease, multiple sclerosis,
type-1 diabetes (T1D), inflammatory bowel disease (IBD), psoriasis
and rheumatoid arthritis, where modulation of a T-cell response is
desirable. The company is accelerating development of
anti-Interleukin 6 receptor (IL6R) mAb, a fully human monoclonal
antibody for treatment of IL6-induced inflammation, especially for
treatment of COVID-19 patients.
Forward-Looking Statements
Certain statements made in this announcement are forward-looking
statements. These forward-looking statements are not historical
facts but rather are based on the Company's current expectations,
estimates, and projections about its industry; its beliefs; and
assumptions. Words such as 'anticipates,' 'expects,' 'intends,'
'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions
are intended to identify forward-looking statements. These
statements are not guarantees of future performance and are subject
to known and unknown risks, uncertainties, and other factors, some
of which are beyond the Company's control, are difficult to
predict, and could cause actual results to differ materially from
those expressed or forecasted in the forward-looking statements.
The Company cautions security holders and prospective security
holders not to place undue reliance on these forward-looking
statements, which reflect the view of the Company only as of the
date of this announcement. The forward-looking statements made in
this announcement relate only to events as of the date on which the
statements are made. The Company will not undertake any obligation
to release publicly any revisions or updates to these
forward-looking statements to reflect events, circumstances, or
unanticipated events occurring after the date of this announcement
except as required by law or by any appropriate regulatory
authority.
For further enquiries:
United Kingdom Investors:
Tiziana Life Sciences plc
Gabriele Cerrone, Chairman and founder +44 (0)20 7495 2379
Cairn Financial Advisers LLP (Nominated Adviser)
Liam Murray / Jo Turner +44 (0)20 7213 0880
Optiva Securities Limited (Broker)
Robert Emmet + 44 (0)20 3981 4173
United States Investors:
Dave Gentry Office 1 800 RED CHIP (733
RedChip Companies Inc. 2447)
Cell 407-491-4498 (USA)
dave@redchip.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
PDIBBBDDGBBDGGI
(END) Dow Jones Newswires
December 18, 2020 06:13 ET (11:13 GMT)
Tiziana Life Sciences (LSE:TILS)
Historical Stock Chart
From Apr 2024 to May 2024
Tiziana Life Sciences (LSE:TILS)
Historical Stock Chart
From May 2023 to May 2024